カテゴリー： GlobalInfoResearch, 世界, 医療/バイオ

肺動脈性肺高血圧症（PAH）医薬品の世界市場2022：カルシウム拮抗薬、新規標的治療薬、その他

◆英語タイトル：Global Pulmonary Arterial Hypertension (PAH) Medicine Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

GlobalInfoResearchが発行した調査報告書（GIR22DC3908）◆商品コード：GIR22DC3908
◆発行会社（リサーチ会社）：GlobalInfoResearch
◆発行日：2023年1月
◆ページ数：95
◆レポート形式：英語 / PDF
◆納品方法：Eメール（注文後2-3日）
◆調査対象地域：グローバル
◆産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

世界の肺動脈性肺高血圧症（PAH）医薬品市場レポートは、グローバル市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
Global Info Research社の最新のリサーチによると、世界の肺動脈性肺高血圧症（PAH）医薬品の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

肺動脈性肺高血圧症（PAH）医薬品市場はタイプとアプリケーションによって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

タイプ別セグメントは次をカバーします。
・カルシウム拮抗薬、新規標的治療薬、その他

アプリケーション別セグメントは次のように区分されます。
・二次性肺高血圧症（SPH）、原発性肺高血圧症（PPH）

世界の肺動脈性肺高血圧症（PAH）医薬品市場の主要な市場プレーヤーは以下のとおりです。
・Pfizer、Gilead Sciences、Eli Lilly、Actelion Pharmaceuticals、United Therapeutics Corporation

地域別セグメントは次の地域・国をカバーします。
・北米（アメリカ、カナダ、メキシコ）
・欧州（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南米（ブラジル、アルゼンチン、コロンビア）
・中東/アフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査資料の内容は計15章あります。
・第1章では、肺動脈性肺高血圧症（PAH）医薬品製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な肺動脈性肺高血圧症（PAH）医薬品メーカーの企業概要、2019年～2022年までの肺動脈性肺高血圧症（PAH）医薬品の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な肺動脈性肺高血圧症（PAH）医薬品メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別肺動脈性肺高血圧症（PAH）医薬品の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までの肺動脈性肺高血圧症（PAH）医薬品の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での肺動脈性肺高血圧症（PAH）医薬品市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および肺動脈性肺高血圧症（PAH）医薬品の産業チェーンを掲載しています。
・第13、14、15章では、肺動脈性肺高血圧症（PAH）医薬品の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
– 肺動脈性肺高血圧症（PAH）医薬品の概要
– 種類別分析（2017年vs2021年vs2028年）：カルシウム拮抗薬、新規標的治療薬、その他
– 用途別分析（2017年vs2021年vs2028年）：二次性肺高血圧症（SPH）、原発性肺高血圧症（PPH）
– 世界の肺動脈性肺高血圧症（PAH）医薬品市場規模・予測
– 世界の肺動脈性肺高血圧症（PAH）医薬品生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– Pfizer、Gilead Sciences、Eli Lilly、Actelion Pharmaceuticals、United Therapeutics Corporation
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：カルシウム拮抗薬、新規標的治療薬、その他
・用途別分析2017年-2028年：二次性肺高血圧症（SPH）、原発性肺高血圧症（PPH）
・肺動脈性肺高血圧症（PAH）医薬品の北米市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・肺動脈性肺高血圧症（PAH）医薬品のヨーロッパ市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・肺動脈性肺高血圧症（PAH）医薬品のアジア市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・肺動脈性肺高血圧症（PAH）医薬品の南米市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・肺動脈性肺高血圧症（PAH）医薬品の中東・アフリカ市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

❖ レポートの目次 ❖

1 Market Overview
1.1 Pulmonary Arterial Hypertension (PAH) Medicine Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Calcium Channel Blockers
1.2.3 Novel Targeted Drugs
1.2.4 Other
1.3 Market Analysis by Application
1.3.1 Overview: Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Secondary Pulmonary Hypertension (SPH)
1.3.3 Primary Pulmonary Hypertension (PPH)
1.4 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size & Forecast
1.4.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales in Volume (2017-2028)
1.4.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Price (2017-2028)
1.5 Global Pulmonary Arterial Hypertension (PAH) Medicine Production Capacity Analysis
1.5.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Total Production Capacity (2017-2028)
1.5.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Pulmonary Arterial Hypertension (PAH) Medicine Market Drivers
1.6.2 Pulmonary Arterial Hypertension (PAH) Medicine Market Restraints
1.6.3 Pulmonary Arterial Hypertension (PAH) Medicine Trends Analysis
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Product and Services
2.1.4 Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Gilead Sciences
2.2.1 Gilead Sciences Details
2.2.2 Gilead Sciences Major Business
2.2.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Product and Services
2.2.4 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Eli Lilly
2.3.1 Eli Lilly Details
2.3.2 Eli Lilly Major Business
2.3.3 Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Product and Services
2.3.4 Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Actelion Pharmaceuticals
2.4.1 Actelion Pharmaceuticals Details
2.4.2 Actelion Pharmaceuticals Major Business
2.4.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Product and Services
2.4.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 United Therapeutics Corporation
2.5.1 United Therapeutics Corporation Details
2.5.2 United Therapeutics Corporation Major Business
2.5.3 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Product and Services
2.5.4 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Pulmonary Arterial Hypertension (PAH) Medicine Breakdown Data by Manufacturer
3.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Pulmonary Arterial Hypertension (PAH) Medicine
3.4 Market Concentration Rate
3.4.1 Top 3 Pulmonary Arterial Hypertension (PAH) Medicine Manufacturer Market Share in 2021
3.4.2 Top 6 Pulmonary Arterial Hypertension (PAH) Medicine Manufacturer Market Share in 2021
3.5 Global Pulmonary Arterial Hypertension (PAH) Medicine Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Pulmonary Arterial Hypertension (PAH) Medicine Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Region
4.1.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales in Volume by Region (2017-2028)
4.1.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region (2017-2028)
4.2 North America Pulmonary Arterial Hypertension (PAH) Medicine Revenue (2017-2028)
4.3 Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue (2017-2028)
4.4 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Revenue (2017-2028)
4.5 South America Pulmonary Arterial Hypertension (PAH) Medicine Revenue (2017-2028)
4.6 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales in Volume by Type (2017-2028)
5.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Type (2017-2028)
5.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales in Volume by Application (2017-2028)
6.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Application (2017-2028)
6.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2017-2028)
7.2 North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2017-2028)
7.3 North America Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country
7.3.1 North America Pulmonary Arterial Hypertension (PAH) Medicine Sales in Volume by Country (2017-2028)
7.3.2 North America Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2017-2028)
8.2 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2017-2028)
8.3 Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country
8.3.1 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales in Volume by Country (2017-2028)
8.3.2 Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2017-2028)
9.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2017-2028)
9.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Region
9.3.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2017-2028)
10.2 South America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2017-2028)
10.3 South America Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country
10.3.1 South America Pulmonary Arterial Hypertension (PAH) Medicine Sales in Volume by Country (2017-2028)
10.3.2 South America Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2017-2028)
11.2 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2017-2028)
11.3 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country
11.3.1 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Pulmonary Arterial Hypertension (PAH) Medicine and Key Manufacturers
12.2 Manufacturing Costs Percentage of Pulmonary Arterial Hypertension (PAH) Medicine
12.3 Pulmonary Arterial Hypertension (PAH) Medicine Production Process
12.4 Pulmonary Arterial Hypertension (PAH) Medicine Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Pulmonary Arterial Hypertension (PAH) Medicine Typical Distributors
13.3 Pulmonary Arterial Hypertension (PAH) Medicine Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Pfizer Basic Information, Manufacturing Base and Competitors
Table 4. Pfizer Major Business
Table 5. Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Product and Services
Table 6. Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Price (USD/Units), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Gilead Sciences Basic Information, Manufacturing Base and Competitors
Table 8. Gilead Sciences Major Business
Table 9. Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Product and Services
Table 10. Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Price (USD/Units), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 12. Eli Lilly Major Business
Table 13. Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Product and Services
Table 14. Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Price (USD/Units), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Actelion Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 16. Actelion Pharmaceuticals Major Business
Table 17. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Product and Services
Table 18. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Price (USD/Units), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. United Therapeutics Corporation Basic Information, Manufacturing Base and Competitors
Table 20. United Therapeutics Corporation Major Business
Table 21. United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Product and Services
Table 22. United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Price (USD/Units), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 24. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 25. Market Position of Manufacturers in Pulmonary Arterial Hypertension (PAH) Medicine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 26. Global Pulmonary Arterial Hypertension (PAH) Medicine Production Capacity by Company, (K Units): 2020 VS 2021
Table 27. Head Office and Pulmonary Arterial Hypertension (PAH) Medicine Production Site of Key Manufacturer
Table 28. Pulmonary Arterial Hypertension (PAH) Medicine New Entrant and Capacity Expansion Plans
Table 29. Pulmonary Arterial Hypertension (PAH) Medicine Mergers & Acquisitions in the Past Five Years
Table 30. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region (2017-2022) & (K Units)
Table 31. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region (2023-2028) & (K Units)
Table 32. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region (2017-2022) & (USD Million)
Table 33. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region (2023-2028) & (USD Million)
Table 34. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2017-2022) & (K Units)
Table 35. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2023-2028) & (K Units)
Table 36. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Type (2017-2022) & (USD Million)
Table 37. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Type (2023-2028) & (USD Million)
Table 38. Global Pulmonary Arterial Hypertension (PAH) Medicine Price by Type (2017-2022) & (USD/Units)
Table 39. Global Pulmonary Arterial Hypertension (PAH) Medicine Price by Type (2023-2028) & (USD/Units)
Table 40. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2017-2022) & (K Units)
Table 41. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2023-2028) & (K Units)
Table 42. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Application (2017-2022) & (USD Million)
Table 43. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Application (2023-2028) & (USD Million)
Table 44. Global Pulmonary Arterial Hypertension (PAH) Medicine Price by Application (2017-2022) & (USD/Units)
Table 45. Global Pulmonary Arterial Hypertension (PAH) Medicine Price by Application (2023-2028) & (USD/Units)
Table 46. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2017-2022) & (K Units)
Table 47. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2023-2028) & (K Units)
Table 48. North America Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2017-2022) & (USD Million)
Table 49. North America Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2023-2028) & (USD Million)
Table 50. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2017-2022) & (K Units)
Table 51. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2023-2028) & (K Units)
Table 52. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2017-2022) & (K Units)
Table 53. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2023-2028) & (K Units)
Table 54. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2017-2022) & (K Units)
Table 55. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2023-2028) & (K Units)
Table 56. Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2017-2022) & (USD Million)
Table 57. Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2023-2028) & (USD Million)
Table 58. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2017-2022) & (K Units)
Table 59. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2023-2028) & (K Units)
Table 60. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2017-2022) & (K Units)
Table 61. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2023-2028) & (K Units)
Table 62. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region (2017-2022) & (K Units)
Table 63. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region (2023-2028) & (K Units)
Table 64. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region (2017-2022) & (USD Million)
Table 65. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region (2023-2028) & (USD Million)
Table 66. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2017-2022) & (K Units)
Table 67. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2023-2028) & (K Units)
Table 68. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2017-2022) & (K Units)
Table 69. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2023-2028) & (K Units)
Table 70. South America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2017-2022) & (K Units)
Table 71. South America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2023-2028) & (K Units)
Table 72. South America Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2017-2022) & (USD Million)
Table 73. South America Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2023-2028) & (USD Million)
Table 74. South America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2017-2022) & (K Units)
Table 75. South America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2023-2028) & (K Units)
Table 76. South America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2017-2022) & (K Units)
Table 77. South America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2023-2028) & (K Units)
Table 78. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region (2017-2022) & (K Units)
Table 79. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region (2023-2028) & (K Units)
Table 80. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region (2017-2022) & (USD Million)
Table 81. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region (2023-2028) & (USD Million)
Table 82. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2017-2022) & (K Units)
Table 83. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2023-2028) & (K Units)
Table 84. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2017-2022) & (K Units)
Table 85. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2023-2028) & (K Units)
Table 86. Pulmonary Arterial Hypertension (PAH) Medicine Raw Material
Table 87. Key Manufacturers of Pulmonary Arterial Hypertension (PAH) Medicine Raw Materials
Table 88. Direct Channel Pros & Cons
Table 89. Indirect Channel Pros & Cons
Table 90. Pulmonary Arterial Hypertension (PAH) Medicine Typical Distributors
Table 91. Pulmonary Arterial Hypertension (PAH) Medicine Typical Customers
List of Figures
Figure 1. Pulmonary Arterial Hypertension (PAH) Medicine Picture
Figure 2. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Type in 2021
Figure 3. Calcium Channel Blockers
Figure 4. Novel Targeted Drugs
Figure 5. Other
Figure 6. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Application in 2021
Figure 7. Secondary Pulmonary Hypertension (SPH)
Figure 8. Primary Pulmonary Hypertension (PPH)
Figure 9. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 10. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue and Forecast (2017-2028) & (USD Million)
Figure 11. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales (2017-2028) & (K Units)
Figure 12. Global Pulmonary Arterial Hypertension (PAH) Medicine Price (2017-2028) & (USD/Units)
Figure 13. Global Pulmonary Arterial Hypertension (PAH) Medicine Production Capacity (2017-2028) & (K Units)
Figure 14. Global Pulmonary Arterial Hypertension (PAH) Medicine Production Capacity by Geographic Region: 2022 VS 2028
Figure 15. Pulmonary Arterial Hypertension (PAH) Medicine Market Drivers
Figure 16. Pulmonary Arterial Hypertension (PAH) Medicine Market Restraints
Figure 17. Pulmonary Arterial Hypertension (PAH) Medicine Market Trends
Figure 18. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Manufacturer in 2021
Figure 19. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Manufacturer in 2021
Figure 20. Pulmonary Arterial Hypertension (PAH) Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 21. Top 3 Pulmonary Arterial Hypertension (PAH) Medicine Manufacturer (Revenue) Market Share in 2021
Figure 22. Top 6 Pulmonary Arterial Hypertension (PAH) Medicine Manufacturer (Revenue) Market Share in 2021
Figure 23. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Region (2017-2028)
Figure 24. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Region (2017-2028)
Figure 25. North America Pulmonary Arterial Hypertension (PAH) Medicine Revenue (2017-2028) & (USD Million)
Figure 26. Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue (2017-2028) & (USD Million)
Figure 27. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Revenue (2017-2028) & (USD Million)
Figure 28. South America Pulmonary Arterial Hypertension (PAH) Medicine Revenue (2017-2028) & (USD Million)
Figure 29. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue (2017-2028) & (USD Million)
Figure 30. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Type (2017-2028)
Figure 31. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Type (2017-2028)
Figure 32. Global Pulmonary Arterial Hypertension (PAH) Medicine Price by Type (2017-2028) & (USD/Units)
Figure 33. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Application (2017-2028)
Figure 34. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Application (2017-2028)
Figure 35. Global Pulmonary Arterial Hypertension (PAH) Medicine Price by Application (2017-2028) & (USD/Units)
Figure 36. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Type (2017-2028)
Figure 37. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Application (2017-2028)
Figure 38. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2017-2028)
Figure 39. North America Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Country (2017-2028)
Figure 40. United States Pulmonary Arterial Hypertension (PAH) Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Canada Pulmonary Arterial Hypertension (PAH) Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Mexico Pulmonary Arterial Hypertension (PAH) Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Type (2017-2028)
Figure 44. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Application (2017-2028)
Figure 45. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2017-2028)
Figure 46. Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Country (2017-2028)
Figure 47. Germany Pulmonary Arterial Hypertension (PAH) Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. France Pulmonary Arterial Hypertension (PAH) Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. United Kingdom Pulmonary Arterial Hypertension (PAH) Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Russia Pulmonary Arterial Hypertension (PAH) Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Italy Pulmonary Arterial Hypertension (PAH) Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Region (2017-2028)
Figure 53. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Application (2017-2028)
Figure 54. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Region (2017-2028)
Figure 55. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Region (2017-2028)
Figure 56. China Pulmonary Arterial Hypertension (PAH) Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Japan Pulmonary Arterial Hypertension (PAH) Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Korea Pulmonary Arterial Hypertension (PAH) Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. India Pulmonary Arterial Hypertension (PAH) Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Southeast Asia Pulmonary Arterial Hypertension (PAH) Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Australia Pulmonary Arterial Hypertension (PAH) Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. South America Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Type (2017-2028)
Figure 63. South America Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Application (2017-2028)
Figure 64. South America Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2017-2028)
Figure 65. South America Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Country (2017-2028)
Figure 66. Brazil Pulmonary Arterial Hypertension (PAH) Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Argentina Pulmonary Arterial Hypertension (PAH) Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Type (2017-2028)
Figure 69. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Application (2017-2028)
Figure 70. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Region (2017-2028)
Figure 71. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Region (2017-2028)
Figure 72. Turkey Pulmonary Arterial Hypertension (PAH) Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Egypt Pulmonary Arterial Hypertension (PAH) Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Saudi Arabia Pulmonary Arterial Hypertension (PAH) Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. South Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Manufacturing Cost Structure Analysis of Pulmonary Arterial Hypertension (PAH) Medicine in 2021
Figure 77. Manufacturing Process Analysis of Pulmonary Arterial Hypertension (PAH) Medicine
Figure 78. Pulmonary Arterial Hypertension (PAH) Medicine Industrial Chain
Figure 79. Sales Channel: Direct Channel vs Indirect Channel
Figure 80. Methodology
Figure 81. Research Process and Data Source


❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 肺動脈性肺高血圧症（PAH）医薬品の世界市場2022：カルシウム拮抗薬、新規標的治療薬、その他(Global Pulmonary Arterial Hypertension (PAH) Medicine Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 肺動脈性肺高血圧症（PAH）治療の世界市場2021-2031：機会分析・産業予測
  • 肺動脈高血圧症治療の世界市場見通し2023年-2029年

    • ◆H&Iグローバルリサーチのお客様（例）◆